What's new?

Sofinnova Partners closes €445M ($540M) oversubscribed late-stage healthcare crossover fund

The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – M...

Henrijette Richter appointed Managing Partner of Sofinnova Partners

BioAmber Signs Its First Succinic Acid Take-­‐or-­‐Pay Contract Contract with PTT-­‐MCC Biochem, a joint venture between Mitsubishi Chemical and PTT PCL

• Contract guarantees sales volume for Sarnia plant during its first three years ofoperation • Agreement ensures BioAmberis the principal supplier to a key emerging buyer of succinic acid • PTTMCC selection of BioAmber as supplier validates bio-­‐succinic cost competitiveness and quality

Plus de 1 00 00 patients ont bénéficié de la technologie auto¬apposante de STENTYS

Paris, le 15 septembre 2011 : STENTYS (FR0010949404 – STNT), société de technologie médicale qui commercialise le premier et le seul stent auto¬apposant pour le traitement de l’infarctus du myocarde, annonce aujourd’hui que son stent autoapposant a été implanté dans plus de 1 000 patients dans le monde.

Inside's ICAO-Lite platform open doors for TIL Technologies

First Commercial ICAO-Lite Deployment Provides Secure, Intelligent Credentials for both Access Control and Identity